Ripple (XRP) has been one of the most mature altcoins with investors betting on its role in cross-border payments and regulatory clarity to drive the next leg higher. However, while XRP offers stability and slow-and-steady growth prospects, a new project, Mutuum Finance (MUTM), is flashing stellar performance potential. MUTM continues its presale at $0.035, but […]Ripple (XRP) has been one of the most mature altcoins with investors betting on its role in cross-border payments and regulatory clarity to drive the next leg higher. However, while XRP offers stability and slow-and-steady growth prospects, a new project, Mutuum Finance (MUTM), is flashing stellar performance potential. MUTM continues its presale at $0.035, but […]

Top 2 Cryptos That Will Create the Most Millionaires in 2025

2025/09/21 23:00
4 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

Ripple (XRP) has been one of the most mature altcoins with investors betting on its role in cross-border payments and regulatory clarity to drive the next leg higher. However, while XRP offers stability and slow-and-steady growth prospects, a new project, Mutuum Finance (MUTM), is flashing stellar performance potential. MUTM continues its presale at $0.035, but it’s developing a lending-and-borrowing protocol that directly targets DeFi demand. 

The project has raised over $16.05 million and has over 16,450 token holders. XRP can potentially turn some of its analysts’ gains into headline material, but MUTM boasts the kind of early-stage momentum that will mint the most new millionaires in 2025.

XRP Trades at $3 as Market Weighs Possible Upsides 

XRP is hovering between $3.00-$3.05 with capped upside and resistance mounting at $3.20 and support at $2.80-$2.90. Sentiment is neutral with some investors pointing to its unmatched position in cross-border settlements and growing traction in institution networks as positives. Upside will, however, be beholden to favorable regulation and macro tailwinds, and past performance suggests that XRP is vulnerable to external catalysts. Compared to the more established profile of XRP, newer DeFi Mutuum Finance is believed by investors to have more percentage growth potential in 2025.

Learning about Mutuum Finance

MUTM dynamically hedges both volatility and liquidity in a manner that allows it to short illiquid positions on good terms. The risk exposure is zero with very low liquidation points. It is paired with ETH and stablecoins and other risk levels of LTV collateralized by less risky assets. It also has a proportionally distributed reserve factor by asset class and one which optimizes the protocol reserve safety.

Mutuum Finance (MUTM) presale is live. Stage 6 presale token buyers can purchase MUTM at $0.035. Over 16,450 investors have already bought tokens, and the project has seen over $16.1 million in investments, a sign of high market demand and extensive launch anticipation.

Mutuum Finance utilizes Chainlink oracles to provide collateral to lend, exchange and settle trades in USD-denominated value of assets and token value of assets like ETH, MATIC and AVAX. Fallback oracle modes, composite data feeds and decentralized exchange time-weighted averages are utilized as error prevention mechanisms. In multi-layered format supply data price can be as accurate as possible even in hard-hitting market conditions.

Market volatility is the biggest source of protocol collateral management. Asset stability is used in LTV and depeg liquidation. For tokens being risky or not, the same minimum and maximum values are used for them. Reserved proportional multiplication is used from 10% less risk to 35% riskier in a way that does not murder diversification.

Building the Future 

Mutuum Finance is developing a passive lending and borrowing protocol that will utilize active management of capital with the potential to allow users to borrow against securitised assets. It operates the platform under a stability algorithm and an interest rate optimisation algorithm on efficiency drivers and long-term resilience of capital utilisation.

Ripple (XRP) and Mutuum Finance (MUTM) are two of the most powerful millionaire-makers through 2025, albeit for entirely different reasons. XRP, trading at approximately $3.00, has been experiencing growing adoption in cross-border payments and possible regulatory tailwinds that can provide consistent upside. 

Mutuum Finance on the other side is in Stage 6 of its presale at $0.035, providing early investors substantially more room for exponential upside. The project is already at $16.05M+ with 16,450+ owners, showing strong demand. With next-gen risk controls, Chainlink oracle integration, and next-gen lending protocol, insiders feel MUTM has the explosive potential that early-stage investors are looking for. Lock in Stage 6 tokens now before the next price surge and position yourself for the highest return in 2025.

For more information regarding Mutuum Finance (MUTM) please use the following links:

Website: https://mutuum.com/

Linktree: https://linktr.ee/mutuumfinance

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09